A Phase 3 Randomized, Double-blind Study Of Pf- 06439535 Plus Paclitaxel-carboplatin And Bevacizumab Plus Paclitaxel -Carboplatin For The First-line Treatment Of Patients With Advanced Non-squamous Non-small Cell Lung Cancer.
Phase of Trial: Phase III
Latest Information Update: 10 Apr 2018
At a glance
- Drugs Bevacizumab (Primary) ; Carboplatin (Primary) ; Paclitaxel (Primary)
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Sponsors Pfizer
- 24 Jan 2018 Status changed from active, no longer recruiting to completed.
- 20 Jan 2018 This trial has been completed in Hungary (end date: 2017-12-12)
- 16 Oct 2017 Planned End Date changed from 8 Dec 2017 to 1 Dec 2017.